ERAS

Erasca, Inc.

Fundamental data last updated:September 25, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.

 


Analyze ERAS on TradingView

VALUATION

P/E

-13.40

Market Cap ($M USD)

$3.79B

Forward P/E

-32.97

PEG

-0.56

PRICE TO SALES

0.00

PRICE TO BOOK

9.43

EV / EBITDA

-29.46

5-Year Average P/E

Free Cash Flow Yield

-2.41%

DCF Value

$0.10

Graham Number

N/A

Price to FCF

-41.53

EV to FCF

-41.51

Earnings Yield

-7.46%

FCF Yield

-2.41%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$0.91

Next Year EPS Growth Estimate

-$0.37

Next Year Revenue Growth Estimate

$281.81M

Return on Equity (ROE)

-77.01%

FREE CASH FLOW

Operating Margin

0.00%

Debt-to-Equity

0.14

Piotroski F-Score

1

Altman Z-Score

31.08

Return on Invested Capital (ROIC)

-32.95%

Current Ratio

9.52

Quick Ratio

9.52

Net Debt to EBITDA

0.01

Interest Coverage

0.00

Gross Profit margin

0.00%

FCF PER SHARE

$-0.30

REVENUE PER SHARE

$0.00

Analyze ERAS on TradingView

Gainseekers Quantitative Analysis

Summary

Erasca, Inc. is a perplexing case of market optimism clashing with financial reality. Despite a staggering Altman Z-score of 23.14 suggesting financial safety, the stock’s valuation metrics paint a different picture. The Forward P/E of -24.10 and an abysmal Earnings Yield of -4.34% indicate a company priced for growth that hasn’t materialized. The market has priced it well above its DCF Value, suggesting a disconnect between expectations and intrinsic value. Investors should tread carefully, as the numbers suggest a speculative bet rather than a value play.

AI Exposure / Tech Reliance

Operating in the biotechnology sector, Erasca is well-positioned to leverage AI advancements for drug discovery and personalized medicine. The industry's inherent reliance on cutting-edge technology gives it a natural resilience to tech shifts. However, execution will be key in translating these opportunities into tangible growth.

The Bull Case

For the optimistic investor, Erasca's high Current Ratio of 10.04 and low Debt/Equity ratio of 0.14 signal robust liquidity and financial prudence. Despite a negative ROIC of -38.33%, the company's ability to maintain a strong balance sheet could provide a cushion for future growth. The Piotroski F-Score of 2 is low, but the biotech sector's potential for explosive growth may justify the risk for those with a high-risk tolerance.

The Bear Case

The bear case for Erasca is glaringly evident in its financial metrics. With a Price/Book ratio of 8.82 and Price/Sales of zero, the stock appears grossly overvalued relative to its tangible assets and revenue generation. The negative FCF Yield of -3.04% and Price to FCF of -32.91 further highlight its cash flow struggles. Trading near its 52-week high, the stock seems technically overextended, making it a risky proposition for conservative investors.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$17.80

Institutional Ownership %

1-Year Beta

0.68

Insider Buying % (6 Mo)

Distance to 52-Week High

99.02%

Distance to 52-Week Low

90.08%

EARNINGS SURPRISE %

4.73%

50-DAY SMA

$14.44

200-DAY SMA

$7.66

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.